Budget impact analysis of the introduction of Rosiglitazone in the treatment of type-2 diabetes. The Italian NHS perspective

被引：0
|
作者：
Novelli, M [1 ]
Avallone, A [1 ]
Frizzo, V [1 ]
Bamfi, F [1 ]
机构：
[1] GlaxoSmithKline Inc, Verona, VR, Italy
来源：
VALUE IN HEALTH | 2005年 / 8卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)67631-0
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A158 / A158
页数：1
相关论文
共 50 条
  • [31] Treatment for Patients with Type-2 Diabetes
    Landgraf, Ruediger
    Kellerer, Monika
    Aberle, Jens
    Fach, Eva-Maria
    Gallwitz, Baptist
    Hamann, Andreas
    Joost, Hans-Georg
    Klein, Harald
    Mueller-Wieland, Dirk
    Nauck, Michael A.
    Reuter, Hans-Martin
    Schreiber, Stephan
    Siegel, Erhard
    DIABETOLOGE, 2019, 15 (02): : 146 - 167
  • [32] Decreased muscle mass in type-2 diabetes. A hidden comorbidity to consider
    de Luis Roman, Daniel
    Garrachon Vallo, Fernando
    Carretero Gomez, Juana
    Jose Lopez Gomez, Juan
    Jose Tarazona Santabalbina, Francisco
    Guzman Rolo, German
    Manuel Garcia Almeida, Jose
    Sanz Paris, Alejandro
    NUTRICION HOSPITALARIA, 2023, 40 : 59 - 66
  • [33] Treatment for Patients with Type-2 Diabetes
    Landgraf, Rueediger
    Aberle, Jens
    Birkenfeld, Andreas L.
    Gallwitz, Baptist
    Kellerer, Monika
    Klein, Harald H.
    Mueller-Wieland, Dirk
    Nauck, Michael A.
    Wiesner, Tobias
    Siegel, Erhard
    DIABETOLOGIE UND STOFFWECHSEL, 2021, 16 : S168 - S206
  • [34] Rosiglitazone is effective in both obese and non-obese patients with type 2 diabetes.
    Cranmer, H
    Jones, NP
    Patwardhan, R
    DIABETOLOGIA, 1999, 42 : A228 - A228
  • [35] A BUDGET IMPACT ANALYSIS OF AN INCREASED UPTAKE OF ALEMTUZUMAB FROM THE UK NHS PERSPECTIVE
    Rog, D.
    Guo, J. D.
    Nucit, A.
    Le Bagousse-Bego, G.
    Chevli, M.
    Chung, L.
    VALUE IN HEALTH, 2017, 20 (09) : A722 - A722
  • [36] The impact of rosiglitazone on heat tolerance in patients with Type 2 Diabetes
    Petrofsky, J
    Lee, S
    Cuneo-Libarona, M
    MEDICAL SCIENCE MONITOR, 2005, 11 (12): : CR562 - CR569
  • [37] BUDGET IMPACT ANALYSIS OF VILDAGLIPTIN AS ADDITION TO ANALOGUE INSULINS IN TYPE 2 DIABETES MELLITUS TREATMENT IN COLOMBIA
    Romero, M.
    Marrugo, R.
    Acero, G.
    Benavides, Karpf F.
    VALUE IN HEALTH, 2014, 17 (03) : A242 - A242
  • [38] Budget impact analysis of continuous glucose monitoring in individuals with type 2 diabetes on insulin treatment in England
    Alsaif, Murtada
    Farhat, Ali
    Blumer, Zoe
    Barham, Leela
    HEALTH ECONOMICS REVIEW, 2024, 14 (01)
  • [39] The economic impact of type-2 diabetes in Europe
    Solignac, M
    DIABETES & METABOLISM, 1999, 25 (06): : U21 - U22
  • [40] Glucagon receptor antagonists for the treatment of type 2 diabetes.
    Handlon, AL
    Akwabi-ameyaw, A
    Brown, K
    De Anda, F
    Drewry, D
    Fang, J
    Irsula, O
    Li, G
    Linn, JA
    Milliken, NO
    Ramanjulu, J
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 226 : U31 - U31
12345